linjc16/ctgov huggingface dataset:
The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia

Study Overview
=================
Brief Summary
-----------------
Complete the examination of cardio-pulmonary ultrasound in accordance with the a-ccue process of patients with novel coronavirus bedside. To summarize and analyze the characteristics of cardiopulmonary ultrasound in patients with novel coronavirus pneumonia, and assess the relationship between pulmonary ultrasound imaging score and National Early Warning Score(NEWS) and prognosis. Auto line B is a method which is based on artificial intelligence is used to calculate the lungs ultrasonic B line numbers reviewing the status of patients with lung, and also evaluate patients' lungs using the traditional artificial semi-quantitative method, to evaluate those two kinds of evaluation methods for the evaluation of patients with lung condition effects are consistent or not, and verify consistency of ultrasonic evaluation method and the way of CT evaluation.

Official Title
-----------------
The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia

Conditions
-----------------
Novel Coronavirus Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >18 years old identify the patients infected with novel coronavirus pneumonia; the patient completed CT examination; sign the informed consent. Exclusion Criteria: age < 18; those who cannot complete cardiopulmonary ultrasound according to the a-ccue process; the patient or his guardian requests to withdraw from the researcher;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| characteristics of cardiopulmonary ultrasound | Complete the examination of cardio-pulmonary ultrasound in accordance with the a-ccue process of patients with novel coronavirus bedside. To summarize and analyze the characteristics of cardiopulmonary ultrasound in patients with novel coronavirus pneumonia | 30 mins | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assess the relationship between pulmonary ultrasound imaging score and National Early Warning Score(NEWS) and prognosis. | assess the relationship between pulmonary ultrasound imaging score and National Early Warning Score(NEWS) and prognosis. | 2-3weeks |
A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

Study Overview
=================
Brief Summary
-----------------
To observe and evaluate the safety and effectiveness of herombopag in the treatment of thrombocytopenia-related diseases in Henan Province

Detailed Description
-----------------
This study is designed as a real-world study on the treatment of thrombocytopenia-related diseases with Herombopag, to observe and analyze the safety and efficacy of Herombopag for thrombocytopenia-related diseases in the real world.

Official Title
-----------------
A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

Conditions
-----------------
Carcinoma;Blood

Intervention / Treatment
-----------------
* Drug: Herombopag


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thrombocytopenia related diseases; Volunteer to join this study and sign an informed consent form; Clinical evaluation can benefit from Herombopag. Exclusion Criteria: Those who have been confirmed to be allergic to Herombopag and/or its excipients; Pregnant or breastfeeding women; Except for patients with contraindications to Herombopag; Doctors evaluate patients who are not suitable for inclusion.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Herombopag|Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events after the treatment of Herombopag | The investigator will observe incidence of adverse events after the treatment of Herombopag, including thrombosis, diarrhea, abnormal liver function and so on. | From the treatment of Herombopag to 28 days after the end of the medication | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes of the platelet counts after the treatment of Herombopag | The investigator will assess the changes of the platelet counts after the treatment of Herombopag。 | From the treatment of Herombopag to 28 days after the end of the medication | 
| Proportion of patients with platelet transfusion | The investigator will assess the proportion of patients with platelet transfusion after the treatment of Herombopag。 | From the treatment of Herombopag to 28 days after the end of the medication |
Comparison of Two Different Procedures for Plexus Anesthesia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the influence of difference positioning on extension and efficacy of brachial plexus anesthesia at 20 minutes by using the axillary plexus block with supine positioning and a lateral positioning onto the non-anaesthetized side, combined with 20° Trendelenburg positioning.

Official Title
-----------------
Comparison of Two Different Procedures for Plexus Anesthesia: Standard Position Versus Combination of Lateral Position and 20° Trendelenburg Position

Conditions
-----------------
Wounds and Injuries

Intervention / Treatment
-----------------
* Procedure: Positioning and plexus anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single shot axillary block Exclusion Criteria: Lateral position not possible

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>combination of lateral position and 20° Trendelenburg Position | Procedure: Positioning and plexus anesthesia<br>* positioning during plexus anesthesia<br>|
| Active Comparator: 2<br>standard positioning | Procedure: Positioning and plexus anesthesia<br>* positioning during plexus anesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extent of anesthesia |  | 20 minutes after acillary plexus block | 
| Efficacy of anesthesia |  | 20 minutes after axillary plexus block | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of failure |  | 20 minutes after axillary plexus block | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
injuries, nerve block, regional anesthesia, diverse malformations
Association Between Oxidative Parameters in Fertilization Medium of Cumulus Oocyte Complex and Outcome in IVF

Study Overview
=================
Brief Summary
-----------------
Medium of cumulus-oocyte complex will be assessed for oxidative status.

Official Title
-----------------
Evaluation of Association Between Oxidative Parameters in Fertilization Medium of Cumulus Oocyte Complex (COC( as Measured by the TCL Assay and Clinical and Laboratory Outcome Parameters in IVF

Conditions
-----------------
Oxidative Stress

Intervention / Treatment
-----------------
* Diagnostic Test: TCL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: •Patients undergoing in vitro fertilization treatment Exclusion Criteria: •Patients undergoing intracytoplasmic sperm injection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: TCL|evaluation of oxidative status|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association of parameters of oxidative state with cycle outcome (pregnancy: yes/no) | The oxidative status in the incubation medium of the cumulus-oocyte complex will be assessed looking for an association between oxidative parameters and cycle outcome (pregnancy: yes/no)) | two years |
Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

Study Overview
=================
Brief Summary
-----------------
Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.

Official Title
-----------------
The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis

Conditions
-----------------
Herpes Labialis

Intervention / Treatment
-----------------
* Drug: NB-001


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 to 80 years of age of either gender Good general health History of recurrent herpes labialis with at least 3 episodes per year Exclusion Criteria: Pregnant and/or nursing female Lesions or irritation on or around the lips that would interfere with recognition of a herpes labialis attack Treatment with topical steroids, antivirals, or new topical products on or around the lips in the week prior to the onset of an attack Known allergies to topical creams, ointments or medications. Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: NB-001|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to healing as assessed by the subject. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of subjects with healing by days 3, 4,and 5 as assessed by the subject. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cold sore
To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets

Study Overview
=================
Brief Summary
-----------------
To demonstrate the relative bioequivalency comparing Geneva's 10 mg Glipizide tablets to Roerig's 10 mg Glucotrol tablets.

Official Title
-----------------
A Two-Way Crossover Bioequivalence Study Comparing Single 10 mg Doses of Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
* Drug: Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.) | Drug: Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)<br> <br> |
| Active Comparator: 2<br>Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.) | Drug: Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence based on AUC and Cmax |  | 9 days |
Therapeutic Virtual Reality: Helps Reduce Anxiety and Pain During Bronchial Fibroscopies in Lung Transplant Patients.

Study Overview
=================
Brief Summary
-----------------
Marie Lannelongue Hospital is a hospital specialized in lung transplantation. Lung transplant patients require regular check-ups by bronchial fibroscopy. This examination is known to be anxious, stressful and sometimes painful. These patients take many medications (immunosuppressants, antibiotics....) that may interact with analgesic or anxiolytic drugs. The objective is to propose to HML lung transplant patients a virtual reality solution containing visual and auditory 3D experiences to fight against anxiety and pain during repetitive and anxiogenic examinations such as bronchial fibroscopies. Translated with www.DeepL.com/Translator (free version)

Official Title
-----------------
Therapeutic Virtual Reality: Helps Reduce Anxiety and Pain During Bronchial Fibroscopies in Lung Transplant Patients.

Conditions
-----------------
Anxiety, Stress, Pain, Bronchial Fibroscopy, Pulmonary Transplantation

Intervention / Treatment
-----------------
* Other: Virtual Reality


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a lung or cardio-pulmonary transplant Adults (age > 18 years old) Patient who give their informed consent for the protocol Patient requiring a bronchial fibroscopy and having already had at least one - bronchial fibroscopy without virtual reality Exclusion Criteria: - children

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Virtual Reality group<br> | Other: Virtual Reality<br>* a bronchial fibroscopy with a virtual reality helmet<br>|
| No Intervention: control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogic Scale (VAS) score from 0 (no anxiety) to 10 (terrified). |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of pain by a score on a numerical scale (EN) from 0 (no pain) to 10 (unbearable pain) |  | 1 day |
Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine

Study Overview
=================
Brief Summary
-----------------
The purpose of this observational study, which will be initiated as soon as the licensed H1N1 Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the incidence of any medically-attended adverse events in all vaccinated subjects.

Official Title
-----------------
A Prospective Non-Interventional Observational Study to Assess the Safety of Two Vaccinations of a Vero Cell-Derived, Whole Virus H1N1 Pandemic Influenza Vaccine in Subjects Exposed to the Vaccine Through Policies by Governments or Health Authorities

Conditions
-----------------
Influenza, Pandemic Influenza

Intervention / Treatment
-----------------
* Biological: H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female subjects, per indication on license or per official vaccine recommendations, will be eligible for participation in this study if: They will be administered CELVAPAN (= Baxter´s H1N1 pandemic influenza vaccine) They are 2 months of age or older at the time of first vaccine administration Their medical history is available The investigator believes they will comply with the foreseen vaccination schedule and will reliably observe signs or symptoms of adverse events during the observational period They and/or their parent(s)/legal guardian(s) provide written informed consent, and assent where appropriate, prior to study entry according to national law Exclusion Criteria: Male and female subjects will be excluded from participation in this study if: They have already been administered another H1N1 pandemic vaccine They have any contraindication to vaccination (as per the Summary of Product Characteristics and/or relevant national immunization guidelines)

Ages Eligible for Study
-----------------
Minimum Age: 2 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| H1N1 Pandemic Influenza Vaccine<br>Subjects will be enrolled and vaccinated according to national policy and standard practice. | Biological: H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)<br>* It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.<br>* Other names: CELVAPAN;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Mininimum Effective Anaesthetic Volume of Local Anaesthetic in Ultrasound-guided Shamrock Lumbar Plexus Block

Study Overview
=================
Brief Summary
-----------------
The Shamrock method is a new ultrasound-guided lumbar plexus block. The aim of the study is to determine the minimum effective volume of ropivacaine 0.5% required to produce an effective lumbar plexus block with this method. Using the Dixon and Massey up-and-down method study design, 30 patients scheduled for elective total hip and knee arthroplasty will be included in the study.

Official Title
-----------------
The Mininimum Effective Anaesthetic Volume of Local Anaesthetic in Ultrasound-guided Shamrock Lumbar Plexus Block

Conditions
-----------------
Mininimum Effective Anaesthetic Volume of Local Anaesthetic

Intervention / Treatment
-----------------
* Other: lumbar plexus block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: orthopaedic patients scheduled for elective hip and knee arthoroplasty ASA 1 - 2 or stable ASA 3 age between 18 and 70 years good ability to communicate and to cooperate Exclusion Criteria: ASA > 3 or unstable ASA 3 BMI > 32 chronicle pain nephrological diseases or nephropathy known contraindications against the use of local anaesthetics pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: injection volume<br>block success or failure determines a 5 ml decrease or increase for the subsequent patient, respectively | Other: lumbar plexus block<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| minimum effective volume | The primary outcome measure (MEV) is based on 30 measurements in 30 patients (secondary outcome measure: block success). MEV is determined by Dixon and Massey up-and-down method when all patients have been tested in the study | from day 1 up to 20 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| block success | 45 minutes after lumbar plexus blockade was performed | Day 1 |